Friday, November 13, 2026

Nikkei 225 Is 8% Up In The Last 21 Sessions

Nikkei 225 Is 8% Up In The Last 21 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 8.48% for the last 21 sessions. At 21:08 EST on Wednesday, 21 June, Nikkei 225 (N225) is $33,583.39.

Regarding Nikkei 225's yearly highs and lows, it's 31.07% up from its 52-week low and 0.56% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was a negative 0.10%, a positive 0.34%, and a positive 0.73%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.58% (last week), 0.96% (last month), and 0.73% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be overbought (>=80).

News about

  • According to Zacks on Tuesday, 20 June, "In the short -term, the S&P 500 Index is approaching a critical "confluence level". ", "On the weekly chart, the S&P 500 Index is running into the 1.618 extension level from the February correction."
  • According to MarketWatch on Tuesday, 20 June, "The stock, which had closed at a record low of 22.5 cents on June 14, has plummeted 93.1% over the past three months through Friday, while the Global X Autonomous and Electric Vehicles exchange-traded fund has climbed 17.3% and the S&P 500 has gained 11.6%."
  • According to DailyForex on Tuesday, 20 June, "The S&P 500 capped its fifth straight week of gains and is now higher than it was on the day the Fed launched its campaign."

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com